v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
 [1]
Current assets:    
Cash and cash equivalents $ 677,911 $ 570,119
Marketable securities 42,249 17,363
Accounts receivable, net 254,484 139,444
Inventories 52,842 26,753
Prepaid expenses and other current assets 65,652 44,070
Total current assets 1,093,138 797,749
Equity method investments 55,095 79,972
Property and equipment, net 5,226 5,366
Operating lease right-of-use assets 17,079 8,149
Intangible assets, net 26,641 28,077
Other assets 20,120 16,712
Total assets 1,217,299 936,025
Current liabilities:    
Accounts payable 27,202 36,228
Accrued compensation and benefits 49,976 76,703
Accrued research and development liabilities 64,468 41,436
Operating lease liabilities, current portion 3,315 6,192
Deferred revenue, current portion 5,546 7,190
Other current liabilities [2] 192,186 120,222
Total current liabilities 890,648 287,971
Deferred royalty obligations, net [3] 879,374 855,030
Operating lease liabilities, net of current portion 14,973 3,811
Deferred revenue, net of current portion 10,424 13,080
Other long-term liabilities 240 244
Total liabilities 3,723,192 3,012,606
Commitments and contingencies (Note 7)
Redeemable convertible noncontrolling interests (1,018) (570)
Stockholders’ deficit:    
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value; 500,000,000 shares authorized; 198,759,831 shares issued and 192,633,286 shares outstanding as of June 30, 2026, 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 206 202
Treasury stock, at cost; 7,597,172 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025 (533,279) (323,276)
Additional paid-in capital 2,155,318 2,057,646
Accumulated other comprehensive income (loss) (7) 12
Accumulated deficit (4,137,453) (3,821,194)
Total BridgeBio stockholders’ deficit (2,515,215) (2,086,610)
Noncontrolling interests 10,340 10,599
Total stockholders’ deficit (2,504,875) (2,076,011) [4]
Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit 1,217,299 936,025
2027 Notes, net    
Current liabilities:    
2027 Notes, net 547,955 0
2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes 0 547,015
2029 Notes, net    
Current liabilities:    
2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes 741,918 740,890
2031 Notes, net    
Current liabilities:    
2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes 565,528 564,565
2033 Notes, net    
Current liabilities:    
2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes $ 620,087 $ 0
[1] The condensed consolidated balance sheet as of December 31, 2025 is derived from the audited consolidated financial statements as of that date.
[2] Including related party amounts of $5,626 and $2,003 as of June 30, 2026 and December 31, 2025, respectively (as described in Note 9).
[3] Including related party amounts of $206,208 and $204,650 as of June 30, 2026 and December 31, 2025, respectively (as described in Note 9).
[4] The consolidated balances as of December 31, 2025 and 2024 are derived from the audited consolidated financial statements as of those dates.